Skip to Content

'
Deborah A. Kuban, M.D., F.A.C.R., F.A.S.T.R.O.

Present Title & Affiliation

Primary Appointment

Professor, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd.
Unit Number: 1202
Houston, TX 77030
Room Number: ACB P1.2864

Education & Training

Degree-Granting Education

1981 Medical College of Georgia, Augusta, GA, MD, Medicine
1977 Valdosta State College, Valdosta, GA, BS, Summa Cum Laude, Biology

Postgraduate Training

6/1982-6/1985 Residency, Radiation Oncology, Eastern Virginia Graduate School of Medicine, Norfolk, VA
6/1981-6/1982 Internship, General Surgery, Eastern Virginia Graduate School of Medicine, Norfolk, VA

Board Certifications

1986 Therapeutic Radiology, American Board of Radiology
1981 Diplomat, National Board of Medical Examiners

Experience/Service

Administrative Appointments/Responsibilities

Medical Director, Genitourinary Center, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2011-present
Director, Radiation Oncology Global Development, The University of Texas MD Anderson Cancer Center, Houston, TX, 7/2010-present
Medical Director, M. D. Anderson Physicians Network, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2009-present
Medical Director, Ad interim, Genitourinary Center, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2009-8/2011
Medical Director, Patient Affairs, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2007-present
Faculty Host Advocate, The University of Texas MD Anderson Cancer Center Physicians Network, Houston, TX, 1/2006-present
Medical Director, Multi-disciplinary Prostate Cancer Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX, 3/2004-present
Genitourinary Section Chief, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 6/2001-present

Consultantships

Scientific Advisory Board, BioTheranostics', San Diego, CA, 2/2011-1/2012
Scientific Advisory Board Member, Ferring Pharmaceuticals, Newtown Square, PA, 9/2009-8/2010

Institutional Committee Activities

Member, M.D. Anderson Cancer Network Strategic Committee, 9/2012-present
Member, Global Academic Programs Steering Committee, 1/2012-present
Member, Physician Relations Faculty Advisory Board, 1/2012-present
Member, Committee on Faculty Awards, 9/2011-8/2012
Member, Banner M. D. Anderson Relationship Committee, 2011-present
Member, Regional Cancer Center Strategic Committee, 2011-2012
Member, M. D. Anderson Physicians Network Annual Symposium Planning Committee, 2010-present
Member, Clinical Effectiveness Subcommittee of the Medical Practice Committee, Working Group on Prostate, Bladder and Testicular Cancer., 2008-present
Member, Genitourinary Center Survivorship Committee, 2008-present
Member, Radiation Oncology Divisional Recruitment Committee, 2007-present
Member, Radiation Oncology Promotion and Tenure Committee, 2007-present
Member, MDAPN Credentials Committee, 2006-present
Member, Division Leadership Committee, Radiation Oncology Department, 2003-present
Member, Genitourinary Center Steering Committee, 2001-present

Honors and Awards

2008 International Who's Who of Professional & Business Women, The American Biographical Institute
2007 Fellow, American Society for Therapeutic Radiology and Oncology
2007 Leading Health Professionals of the World, Cambridge, England
2006 Fellow, American College of Radiology
2003 Faculty of 1000 in Medicine, Philadelphia, PA
2003 The Global Directory of Who's Who, New York, NY
2002 Houston's Best Doctors, Inside Houston Magazine
2002 Houston's Best Women Doctors, Inside Houston Magazine
1992 Listed among the Best Cancer Specialists in the U.S., Radiation Oncology, Genitourinary, Good Housekeeping Magazine

Professional Memberships

American Board of Radiology
Oral Board Examiner, 1994-present
American Society for Radiation Oncology
Chair, Corporate Relations Committee of the Education Council, 2009-present
Member, Research Council Evidence-based clinical practice guideline: Role of post-operative radiotherapy for radical prostatectomy panel, 2007-present
American Society of Clinical Oncology
Member, Roster of Cancer Experts, 2005-present
N.C.I. Cancer Therapy Evaluation Program (CTEP)
Co-Chair, Prostate Cancer Task Force of The G.U. Steering Committee, 2009-present
National Comprehensive Cancer Network
Member, Bladder Cancer Guidelines Panel, 2007-present
Quality Research in Radiation Oncology Committee (QRRO)
Member, 2007-present
Radiation Oncology Institute
Nominating Committee Member, 2011-present
Vice President, 2011-present
Board of Trustees Member, 2009-present
Campaign Cabinet Member, 2008-present
Radiation Therapy Oncology Group
Member, Genitourinary Committee, 2001-present
Texas Medical Society
Member, 2008-present
U.S. Department of Defense Prostate Cancer Research Program, Frederick, MD
Integration Panel Member, 1/2012-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Li X, Quan EM, Li Y, Pan X, Zhou Y, Wang X, Du W, Kudchadker RJ, Johnson JL, Kuban DA, Lee AK, Zhang X. A Fully Automated Method for CT-on-Rails-Guided Online Adaptive Planning for Prostate Cancer Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys 86(5):835-41, 8/1/2013. e-Pub 5/29/2013. PMID: 23726001.
2. Hamstra DA, Conlon AS, Daignault S, Dunn RL, Sandler HM, Hembroff AL, Zietman AL, Kaplan I, Ciezki J, Kuban DA, Wei JT, Sanda MG, Michalski JM, PROSTQA Consortium Study Group. Multi-institutional Prospective Evaluation of Bowel Quality of Life After Prostate External Beam Radiation Therapy Identifies Patient and Treatment Factors Associated With Patient-Reported Outcomes: The PROSTQA Experience. Int J Radiat Oncol Biol Phys 86(3):546-53, 7/1/2013. e-Pub 4/2/2013. PMID: 23561651.
3. Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Spiess PE, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M. Bladder cancer. J Natl Compr Canc Netw 11(4):446-75, 4/1/2013. PMID: 23584347.
4. Beard CJ, Travis LB, Chen MH, Arvold ND, Nguyen PL, Martin NE, Kuban DA, Ng AK, Hoffman KE. Outcomes in stage I testicular seminoma: A population-based study of 9193 patients. Cancer. e-Pub 4/30/2013. PMID: 23633409.
5. Pair ML, Du W, Rojas HD, Kanke JE, McGuire SE, Lee AK, Kuban DA, Kudchadker RJ. Dosimetric effects of weight loss or gain during volumetric modulated arc therapy and intensity-modulated radiation therapy for prostate cancer. Med Dosim. e-Pub 3/26/2013. PMID: 23540491.
6. Castle KO, Hoffman KE, Levy LB, Lee AK, Choi S, Nguyen QN, Frank SJ, Pugh TJ, McGuire SE, Kuban DA. Is Androgen Deprivation Therapy Necessary in All Intermediate-Risk Prostate Cancer Patients Treated in the Dose Escalation Era? Int J Radiat Oncol Biol Phys 85(3):693-9, 3/1/2013. e-Pub 7/24/2012. PMID: 22836052.
7. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P. Prostate specific antigen best practice statement: 2009 update. J Urol 189(1 Suppl):S2-S11, 1/2013. PMID: 23234625.
8. McGuire SE, Lee AK, Cerne JZ, Munsell MF, Levy LB, Kudchadker RJ, Choi SL, Nguyen QN, Hoffman KE, Pugh TJ, Frank SJ, Corn PG, Logothetis CJ, Kuban DA. PSA Response to Neoadjuvant Androgen Deprivation Therapy Is a Strong Independent Predictor of Survival in High-Risk Prostate Cancer in the Dose-Escalated Radiation Therapy Era. Int J Radiat Oncol Biol Phys. e-Pub 10/23/2012. PMID: 23102837.
9. Pugh TJ, Frank SJ, Achim M, Kuban DA, Lee AK, Hoffman KE, McGuire SE, Swanson DA, Kudchadker R, Davis JW. Endorectal magnetic resonance imaging for predicting pathologic T3ádisease in Gleason score 7áprostate cancer: Implications foráprostateábrachytherapy. Brachytherapy. e-Pub 6/5/2012. PMID: 22673704.
10. Quan EM, Li X, Li Y, Wang X, Kudchadker RJ, Johnson JL, Kuban DA, Lee AK, Zhang X. A Comprehensive Comparison of IMRT and VMAT Plan Quality for Prostate Cancer Treatment. Int J Radiat Oncol Biol Phys 83(4):1169-78, 2012. PMID: 22704703.
11. Bian SX, Kuban DA, Levy LB, Oh J, Castle KO, Pugh TJ, Choi S, McGuire SE, Nguyen QN, Frank SJ, Nguyen PL, Lee AK, Hoffman KE. Addition of short-term androgen deprivation therapy to dose-escalated radiation therapy improves failure-free survival for select men with intermediate-risk prostate cancer. Ann Oncol 9:2346-52, 2012. PMID: 22357249.
12. Vassiliev ON, Kudchadker RJ, Kuban DA, Frank SJ, Choi S, Nguyen QN, Lee AK. Dosimetric impact of fiducial markers in patients undergoing photon beam radiation therapy. Phys Med 28(3):240-4, 2012. PMID: 21875820.
13. Kim MM, Hoffman KE, Levy LB, Frank SJ, Pugh TJ, Choi S, Nguyen QN, McGuire SE, Lee AK, Kuban DA. Improvement in prostate cancer survival over time: a 20-year analysis. Cancer J 18(1):1-8, 2012. PMID: 22290249.
14. Fisher CM, Troncoso P, Swanson DA, Munsell MF, Kuban DA, Lee AK, Yeh SF, Frank SJ. Knife or needles? A cohort analysis of outcomes after radical prostatectomy or brachytherapy for men with low- or intermediate-risk adenocarcinoma of the prostate. Brachytherapy 11(6):429-34, 2012. PMID: 22727472.
15. Brooks C, Sheu T, Bridges K, Mason K, Kuban D, Mathew P, Meyn R. Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer. Radiat Oncol 7(1):154, 2012. PMID: 22967802.
16. Kim MM, Hoffman KE, Levy LB, Frank SJ, Pugh TJ, Choi S, Nguyen QN, McGuire SE, Lee AK, Kuban DA. Prostate cancer-specific mortality after definitive radiation therapy: Who dies of disease? Eur J Cancer 48(11):1664-71, 2012. PMID: 22336663.
17. Sharp HJ, Swanson DA, Pugh TJ, Zhang M, Phan J, Kudchadker R, Bruno TL, Kuban DA, Lee AK, Choi S, Nguyen QN, Hoffman KE, McGuire SE, Frank SJ. Screening Colonoscopy Before Prostate Cancer Treatment Can Detect Colorectal Cancers in Asymptomatic Patients and Reduce the Rate of Complications After Brachytherapy. PRO 2(3):e7, 2012.
18. Boonsirikamchai P, Kaur H, Kuban DA, Jackson E, Hou P, Choi H. Use of maximum slope images generated from dynamic contrast-enhanced MRI to detect locally recurrent prostate carcinoma after prostatectomy: a practical approach. AJR Am J Roentgenol 198(3):W228-36, 2012. PMID: 22358019.
19. Samuelian JM, Swanson DA, Kudchadker RJ, Pugh TJ, Kuban DA, Lee AK, Choi S, Nguyen QN, Bruno TL, Frank SJ. Long-term tumor control after brachytherapy for base-of-prostate cancer. J Contemp Brachytherapy 3(4):183-7, 12/2011. e-Pub 12/30/2011. PMCID: PMC3551361.
20. Kuban DA, Levy LB, Cheung MR, Lee AK, Choi S, Frank S, Pollack A. Long-term Failure Patterns and Survival in a Randomized Dose-Escalation Trial for Prostate Cancer. Who Dies of Disease? Int J Radiat Oncol Biol Phys 79(5):1310-7, 2011. PMID: 20493642.
21. Alemozaffar M, Regan MM, Cooperberg MR, Wei JT, Michalski JM, Sandler HM, Hembroff L, Sadetsky N, Saigal CS, Litwin MS, Klein E, Kibel AS, Hamstra DA, Pisters LL, Kuban DA, Kaplan ID, Wood DP, Ciezki J, Dunn RL, Carroll PR, Sanda MG. Prediction of erectile function following treatment for prostate cancer. JAMA 306(11):1205-14, 2011. PMID: 21934053.
22. Hoffman KE, Nguyen PL, Chen MH, Chen RC, Choueiri TK, Hu JC, Kuban DA, D'Amico AV. Recommendations for post-prostatectomy radiation therapy in the United States before and after the presentation of randomized trials. J Urol 185(1):116-20, 2011. PMID: 21074194.
23. Iyengar P, Levy LB, Choi S, Lee AK, Kuban DA. Toxicity Associated With Postoperative Radiation Therapy for Prostate Cancer. Am J Clin Oncol 34(6):611-8, 2011. PMID: 21150565.
24. Frank SJ, Kudchadker RJ, Kuban DA, De Crevoisier R, Lee AK, Cheung RM, Choi S, Tucker SL, Dong L. A Volumetric Trend Analysis of the Prostate and Seminal Vesicles During a Course of Intensity-Modulated Radiation Therapy. Am J Clin Oncol 33(2):173-5, 2010. PMID: 20010077.
25. Tucker SL, Dong L, Bosch WR, Michalski J, Winter K, Mohan R, Purdy JA, Kuban D, Lee AK, Cheung MR, Thames HD, Cox JD. Late Rectal Toxicity on RTOG 94-06: Analysis Using a Mixture Lyman Model. Int J Radiat Oncol Biol Phys 78(4):1253-60, 2010.
26. Thames HD, Kuban D, Levy LB, Horwitz EM, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 men treated between 1987 and 1995. Radiother Oncol 96(1):6-12, 2010. PMID: 20400191.
27. Archambault L, Briere TM, P÷nisch F, Beaulieu L, Kuban DA, Lee A, Beddar S. Toward a Real-Time In Vivo Dosimetry System Using Plastic Scintillation Detectors. Int J Radiat Oncol Biol Phys 78(1):280-7, 2010.
28. Madsen LT, Craig C, Kuban D. A multidisciplinary prostate cancer clinic for newly diagnosed patients: developing the role of the advanced practice nurse. Clin J Oncol Nurs 13(3):305-9, 2009. PMID: 19502188.
29. Montie JE, Clark PE, Eisenberger MA, El-Galley R, Greenberg RE, Herr HW, Hudes GR, Kuban DA, Kuzel TM, Lange PH, Lele SM, Michalski J, Patterson A, Pohar KS, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Walther PJ, Wilson TG, Wilson TG. Bladder cancer. J Natl Compr Canc Netw 7(1):8-39, 2009. PMID: 19176203.
30. Tu SM, Lopez A, Leibovici D, Bilen M, Evliyaoglu F, General RD, Aparicio A, Pagliaro LC, Guo CC, Kuban DA, Johnson MM, Logothetis CJ, Lin SH, Pisters LL. Ductal Adenocarcinoma of the Prostate - Clinical Features and Implications After Local Therapy. Cancer 115(13):2872-80, 2009. PMID: 19402048.
31. Cox JD, Giralt SA, Veazie ML, Ajani JA, Bruner JM, Chan KW, Hittelman WN, Hunt KK, Iyer RB, Karp DD, Kuban DA, Lippman SM, Raad II, Rodriguez-Bigas MA, Zwelling LA, Markman M. Evaluating Quality in Clinical Cancer Research: The M.D. Anderson Cancer Center Experience. Oncology 77(2):75-81, 2009. PMID: 19571599.
32. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P. Prostate specific antigen best practice statement: 2009 update. J Urol 182(5):2232-41, 2009. PMID: 19781717.
33. Frank SJ, Levy LB, Kuban DA, Lee AK, Kudchadker RJ, Bruno TL, Vulpen MV, Swanson DA. Prostogram Predicted Brachytherapy Outcomes are Not Universally Accurate: An Analysis Based on the M. D. Anderson Cancer Center Experience With (125)Iodine Brachytherapy. J Urol 181(4):1658-63, 2009. PMID: 19233434.
34. Williams BJ, Fox BD, Sciubba DM, Suki D, Tu SM, Kuban D, Gokaslan ZL, Rhines LD, Rao G. Surgical management of prostate cancer metastatic to the spine. J Neurosurg Spine 10(5):414-22, 2009. PMID: 19442002.
35. Anderson JF, Swanson DA, Levy LB, Kuban DA, Lee AK, Kudchadker R, Phan J, Bruno T, Frank SJ. Urinary side effects and complications after permanent prostate brachytherapy: the MD Anderson Cancer Center experience. Urology 74(3):601-5, 2009. PMID: 19589580.
36. Lawton C, Michalski J, El-Naqa I, Kuban D, Lee W, Rosenthal S, Zietman A, Sandler H, Shipley W, Ritter M, Valicenti R, Cattan C, Roach M, Pisansky T, Seider M.. Variation in the Definition of Clinical Target Volumes for Pelvic Nodal Conformal Radiation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys 74(2):377-82, 2009. PMID: 18947941.
37. Trabulsi EJ, Valicenti RK, Hanlon AL, Pisansky TM, Sandler HM, Kuban DA, Catton CN, Muchalski JM, Zefelsky MJ, Kupelian PA, Lin DW, Anscher MS, Slawin KM, Roehrborn CG, Forman JD, Liauw SL, Kestin L, Deweese TL. Scardino PT, Stephenson AJ, Pollack A. A Multi-Institutional Matched-Control Analysis of Adjuvant and Salvage Postoperative Radiation Therapy for pT3-4N0 Prostate Cancer. Urology 72(6):1298-302, 2008. PMID: 18672274.
38. O'Daniel, Dong L, Zhang J, Wang C, Tucker S, Kudchadker R, Lee AK, Cheung MR, Cox J, Kuban D, Mohan R. Daily bone alignment with limited repeat CT correction rivals daily ultrasound alignment for prostate radiotherapy. Int J Radiat Oncol Biol Phys 71(1):274-280, 2008.
39. Kudchadker RJ, Swanson DA, Kuban DA, Lee AK, Bruno TL, Frank SJ. Is a Loose-Seed Nomogram Still Valid for Prostate Brachytherapy in a Stranded-Seed Era? Int J Radiat Oncol Biol Phys. 72(2):623-7, 2008. PMID: 18410998.
40. Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, Lee AK, Pollack A. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70(1):67-74, 2008. PMID: 17765406.
41. Wang H, Garden AS, Zhang L, Wei X, Ahamad A, Kuban DA, Komaki R, O'Daniel J, Zhang Y, Mohan R, Dong L. Performance evaluation of automatic anatomy segmentation algorithm on repeat or four-dimensional computed tomography images using deformable image registration method. Int J Radiat Oncol Biol Phys 72(1):210-9, 2008. PMID: 18722272.
42. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, Mahadevan A, Klein E, Kibel A, Pisters LL, Kuban D, Kaplan I, Wood D, Ciezki J, Shah N, Wei JT. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358(12):1250-61, 2008. PMID: 18354103.
43. Frank SJ, Dong L, Kudchadker RJ, De Crevoisier R, Lee AK, Cheung R, Choi S, O'Daniel J, Tucker SL, Wang H, Kuban DA. Quantification of prostate and seminal vesicle interfraction variation during IMRT. Int J Radiat Oncol Biol Phys 71(3):813-20, 2008. PMID: 18207664.
44. Frank SJ, Pisters LL, Davis J, Lee AK, Bassett R, Kuban DA. An assessment of quality of life following radical prostatectomy, high-dose external beam radiation therapy, and brachytherapy iodine implantation as monotherapies for localized prostate cancer. J Urol 177(6):2151-6, 2007. PMID: 17509305.
45. de Crevoisier R, Melancon AD, Kuban DA, Lee AK, Cheung RM, Tucker SL, Kudchadker RJ, Newhauser WD, Zhang L, Mohan R, Dong L. Changes in the Pelvic Anatomy After an IMRT Treatment Fraction of Prostate Cancer. Int J Radiat Oncol Biol Phys 68(5):1529-36, 2007. PMID: 17544595.
46. Zhang X, Dong L, Lee AK, Cox JD, Kuban DA, Zhu RX, Wang X, Li Y, Newhauser WD, Gillin M, Mohan R. Effect of anatomic motion on proton therapy dose distributions in prostate cancer treatment. Int J Radiat Oncol Biol Phys 67(2):620-9, 2007. PMID: 17236979.
47. Frank SJ, Grimm PD, Sylvester JE, Merrick GS, Davis BJ, Zietman A, Moran BJ, Beyer DC, Roach M, Clarke DH, Stock RG, Robert Lee W, Michalski JM, Wallner KE, Hurwitz M, Potters L, Kuban DA, Prestidge BR, Vera R, Hathaway S, Blasko JC. Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: A survey of practice patterns in the United States. Brachytherapy 6(1):2-8, 2007. PMID: 17284379.
48. Cheung MR, Tucker SL, Dong L, de Crevoisier R, Lee AK, Frank S, Kudchadker RJ, Thames H, Mohan R, Kuban D. Investigation of bladder dose and volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 67(4):1059-65, 2007. PMID: 17241755.
49. Melancon AD, O'Daniel JC, Zhang L, Kudchadker RJ, Kuban DA, Lee AK, Cheung RM, de Crevoisier R, Tucker SL, Newhauser WD, Mohan R, Dong L. Is a 3-mm intrafractional margin sufficient for daily image-guided intensity-modulated radiation therapy of prostate cancer? Radiother Oncol 85(2):251-259, 2007. PMID: 17892900.
50. Zelefsky MJ, Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, Moran BJ, Ciezki JP, Zietman AL, Pisansky TM, Elshaikh M, Horwitz EM. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 67:327-33, 2007. PMID: 17084558.
51. Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, Anscher MS, Michalski JM, Sandler HM, Lin DW, Forman JD, Zelefsky MJ, Kestin LL, Roehrborn CG, Catton CN, DeWeese TL, Liauw SL, Valicenti RK, Kuban DA, Pollack A. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. Am J Clin Oncol 25(15):2035-41, 2007. PMID: 17513807.
52. Feng M, Hanlon AL, Pisansky TM, Kuban D, Catton CN, Michalski JM, Zelefsky MJ, Kupelian PA, Pollack A, Kestin LL, Valicenti RK, Deweese TL, Sandler HM. Predictive Factors for late Genitourinary and Gastrointestinal Toxicity in Patients With Prostate Cancer Treated With Adjuvant or Salvage Radiotherapy. Int J Radiat Oncol Biol Phys 68(5):1417-23, 2007. PMID: 17418972.
53. Vance W, Tucker SL, de Crevoisier R, Kuban DA, Cheung MR. The predictive value of 2-year posttreatment biopsy after prostate cancer radiotherapy for eventual biochemical outcome. Int J Radiat Oncol Biol Phys 67(3):828-33, 2007. PMID: 17161554.
54. Vassiliev ON, Kry SF, Kuban DA, Salehpour M, Mohan R, Titt U. Treatment-planning study of prostate cancer intensity-modulated radiotherapy with a Varian Clinac operated without a flattening filter. Int J Radiat Oncol Biol Phys 68(5):1567-71, 2007. PMID: 17544596.
55. Kry SF, Followill D, White RA, Stovall M, Kuban DA, Salehpour M. Uncertainty of calculated risk estimates for secondary malignancies after radiotherapy. Int J Radiat Oncol Biol Phys 68(4):1265-71, 2007. PMID: 17637398.

Invited Articles

1. Bellmunt J, Attard G, Bahl A, Huland H, Klotz L, Kuban D, Oudard S, Watson W. Advances in the management of high-risk localised and metastatic prostate cancer. BJU Int 109(Suppl 2):8-13, 2012. PMID: 22257099.
2. Carducci MA, Montie JE, Kuban DA. Perspectives on the Management of Localized Prostate Cancer. American Society of Clinical Oncology, Educational Book, 2009.

Editorials

1. Kuban DA. Localized prostate cancer: the battle of treatment options enters the larger arena. Oncology (Williston Park) 23(10):867, 873, 2009. PMID: 19839428.
2. Kuban DA, Pagliaro L. Salvage Radiotherapy or Observation After Radical Prostatectomy in the PSA era. The American Journal of Hematology/Oncology. 8(3):136-138, 2009.
3. Kuban DA. Reconsidering the case for brachytherapy plus EBRT in high-risk prostate cancer. Oncology 22:1006-1012, 2008.
Other Articles
1. Kuban DA. Book Review of Image-Guided Radiation Therapy of Prostate Cancer. Int J Rad Oncol Biol Phys, 2008.

Abstracts

1. Skiner HD, McCurdy M, Echeverria A, Lin S, Welsh J, O'Reily M, Hofstetter W, Ajani J, Komaki R, Guerrero T. Metformin Use is Associated With Improved Response to Neoadjuvant Chemoradiation In Esophageal Adenocarcinoma. Int J Rad Oncol Biol Phys 84(35):S41, 11/2012.
2. Bian S, Kuban DA, Levy LB, Oh J, Choi S, McGuire SE, Pugh TJ, Nguyen PL, Lee AK, Hoffman KE. The Influence of Age and Comorbidity on the Benefit of Adding Androgen Deprivation to Dose-escaleted Radiation in Men With Intermediate-Risk Prostate Cancer. Int J Rad Oncol Biol Phys 84(35):S370, 11/2012.
3. Corn PG, Song D, Heath E, Maier J, Meyn R, Kuban D, DiPetrillo T, Mathew P. Sunitinib plus hormone ablation and radiation therapy for patients with high-risk localized prostate cancer: results from a multi-institutional phase 1 study. Proceedings of the American Association of Cancer Research Annual Meeting 2012 (#741), 4/2012.
4. Choi S, Umfleet WE, Palmer MB, Nguyen QN, McGuire SE, Pugh TJ, Kuban DA, Lee AK. Comparison of Scanning Beam Proton Therapy (SBPT) to Intensity Modulated X-ray Therapy (IMRT) for Postoperative Salvage Treatment of Prostate Cancer Patients. Int J Rad Oncol Biol Phys 84(35):S843, 2012.
5. Mahmood U, Koshy M, Pugh TJ, Hoffman KE, Kuban DA, Lee AK. Decreasing Utilization of Brachytherapy for the Treatment of Prostate Cancer: A National Pattern of Care Analysis Using NCCN Risk Categorization. Int J Rad Oncol Biol Phys 84(35):S399, 2012.
6. Lee AK, Choi S, Nguyen Q, Pugh T, Mathai B, Frank SJ, Hoffman K, Kuban D, McGuire S, Munsell MF. Patient Quality of Life After Proton Therapy (1.8 vs 2 Gray Equivalents) for Prostate Cancer. Int J Rad Oncol Biol Phys 84(35):S366, 2012.
7. Pugh TJ, Choi S, Nguyen QN, De Gracia B, Munsell MF, Frank SJ, Kuban DA, Hoffman KE, McGuire SE, Lee AK. Prospective Quality of Life Toxicity Between Passively Scattered and Spot Scanning Proton Therapy for Prostate Cancer. Int J Rad Oncol Biol Phys 84(35):S384, 2012.
8. Nguyen QN, Wages C, Palmer M, Choi S, Pugh TJ, Kuban DA, Lee AK. Scanning Beam Proton Therapy Reduces Dose to Normal Tissue Compared to 3-dimensional X-rays or Passively-Scattered Proton Therapy in Patients With Stage I Seminoma. Int J Rad Oncol Biol Phys 84(35):S844, 2012.
9. Hoffman KE, Kim J, Davis JW, Choi S, Pettaway C, Lee AK, Domain D, Levy LB, Madsen LT, Kuban DA. Barriers to Active Surveillance as a Treatment Choice for Prostate Cancer. Int J Rad Oncol Biol Phys 81(2):S141-S142, 2011.
10. Domain D, Hoffman KE, Madsen LT, Pettaway CA, Kim J, Davis JW, Lee AK, Pisters L, Levy LB, Kuban DA. Clinical Trial Enrollment in a Multidisciplinary Prostate Cancer Clinic. Int J Rad Oncol Biol Phys 81(2):S555, 2011.
11. Choi S, Amin M, Palmer M, Zhu XR, Nguyen QN, Pugh TJ, Kuban DA, Lee AK. Comparison of Intensity Modulated Proton Therapy (IMPT) to Passively Scattered Proton Therapy (PSPT) in the Treatment of Prostate Cancer. Int J Rad Oncol Biol Phys 81(2):S154-S155, 2011.
12. Bian SX, Kuban DA, Levy LB, Oh J, Castle KO, Pugh TJ, CHoi S, McGuire SE, Nguyen QN, Frank SJ, Nguyen PL, Lee AK, Hoffman KE. Effect of adding Short-Term Androgen Deprivation Therapy to Dose-Escalated Radiation Therapy on Failure-Free Survival for Select Men with Intermediate Risk Prostate Cancer. Proceedings of The 2011 Genitourinary Cancer Symposium (#176), 2011.
13. Hoffman, KE, Chen M, Nguyen PL, Bennett CL, Sartor AO, Stein K, Kuban DA, D'Amico AV. Factors Associated With a Delay in Diagnosis of Recurrent Prostate Cancer After Radical Prostatectomy. Proceedings of the 2011 Genitourinary Cancers Symposium (#208), 2011.
14. Castle KO, Hoffman KE, Levy LB, Lee AK, Choi S, Nguyen QN, Frank SJ, Pugh TJ, McGuire SE, Kuban DA. Is Androgen Deprivation Therapy Necessary in Intermediate Risk Prostate Cancer Patients Treated in the Dose Escalation Era?. Int J Rad Oncol Biol Phys 81(2):S40-S41, 2011.
15. Frank SJ, Kudchadker R, Pugh TJ, Munsell MF, Lee AK, Kuban DA, Bruno t, Swanson DA. Long-Term Outcomes, Quality of Life, and Patient Reported Satisfaction Following Prostate Brachytherapy: The M.D. Anderson Cancer Center Experience. Proceedings of the American Brachytherapy Society Annual Meeting (#299), 2011.
16. Pugh TJ, Frank SJ, Achim M, Kuban DA, Lee AK, Choi S, Nguyen QN, Hoffman KH, McGuire SE, Swanson DA. Prediction of Extraprostatic Extension in Intermediate Risk Prostate Cancer: The Evolving Role of Endorectal MRI. Int J Rad Oncol Biol Phys 81(2):S398, 2011.
17. Hoffman KE, Madsen LT, Levy LB, Pettaway C, Pisters L, Choi S, Kim J, Davis JW, Ward JF, Kuban DA. Prostate Cancer Treatment Selection after Counseling in a Multidisciplinary Prostate Cancer Clinic. Int J Rad Oncol Biol Phys 81(2):S563-S564, 2011.
18. Kim MM, Hoffman KE, Levy LB, Frank SJ, Choi S, Nguyen QN, Pugh TJ, McGuire SE, Lee AK, Kuban DA. Prostate Cancer-Specific Mortality After Definitive Radiation Therapy: Who Dies of Disease?. Proceedings of the 2011 Genitourinary Cancers Symposium (#181), 2011.
19. Nguyen QN, Crawford C, Palmer M, Zhu R, Choi S, Pugh TJ, Frank SJ, Hoffman KE, Kuban DA,. Utilizing A Multifield Optimization Intensity Modulated Proton Technique (MFO-IMPT) To Deliver A Simultaneous Integrated Boost (SIB) To The Dominant Intraprostatic Lesion For Localized Prostate Cancer. Int J Rad Oncol Biol Phys 81(2):S876-S877, 2011.
20. Morikawa LK, Kudchadker R, Kanke J, Oyervides M, Frank SJ, Lee AK, Hoffman KE, Nguyen QN, Kuban DA. Endorectal Balloon in Post-operative Radiation Therapy for Prostate Cancer. Int J Rad Oncol Phys 78(3):S395 (#2429), 2010.
21. Morikawa L, Levy LB, Lee AK, Choi S, Nguyen QN, Frank SJ, Kuban DA. Endorectal Balloon in Post-Operative Radiation Therapy for Prostate Cancer Patients. Proceedings of The 40th Jornada Paulista Radiologia. 2010.
22. Kudchadker RJ, Nguyen QN, Vu K, Wooton L, Choi S, Frank SJ, Johnson JL, Kuban DA, Lee AK. Evaluation of the use of air or water filled endorectal balloons for prostate IMRT patients. Proceedings of The American Association of Medical Physics Annual Meeting, 2010.
23. Kim MM, Hoffman KE, Levy LB, Master P, Frank SJ, Choi S, Nguyen QN, McGuire SE, Lee AK, Kuban DA. Improvement in Prostate Cancer Outcomes Over Time: A Twenty-Year Analysis. Int J Rad Oncol Phys 78(3):S191 (#1115), 2010.
24. Ludwig MS, Lee AK, McGuire SE, Choi S, Nguyen QN, Frank SJ, Kuban DA. Influence of Prognostic Factors on Duration of Hormone Therapy and Outcomes. Proceedings of the 92nd Annual Meeting of The American Radium Society, 2010.
25. Bolukbasi Y, Levy LB, Lee AK, Choi S, Frank SJ, Nguyen QN, Kuban DA. Long-Term Results of Adjuvant and Salvage Radiotherapy After Radical Prostatectomy. Proceedings of the 2010 Genitourinary Cancers Symposium. (#118), 2010.
26. Meyn RE, Mason KA, Brooks C, Mathew P, Sheu T, Kuban DA. Preclinical Evaluation of Sunitib, a Multi Tyrosine Kinase Inhibitor as a Radiosensitizer for Human Prostate Cancer. Int J Rad Oncol Phys 78(3):S651 (#3002), 2010.
27. Kuban DA, Noueras-Gonzalez GM, Hamblin L, Lee AK, Coi S, Frank SJ, Nguyen QN, Hoffman KE, McGuire SE, Munsell MF. Preliminary Report of a Randomized Dose Escalation Trial for Prostate Cancer using Hypofractionation. Int J Rad Oncol Phys 78(3):S58 (#124), 2010.
28. Fisher CM, Troncoso P, Swanson DA, Munsell MF, Lee AK, Choi S, Nguyen QN, Frank SJ. Prostate Cancer-specific Survival and Time to Recurrence Outcomes for Men Treated with Radical Prostatectomy, Intensity Modulated Radiation Therapy, or Brachytherapy at M.D. Anderson Cancer Center. Int J Rad Oncol Phys 78(3):S147 (#1017), 2010.
29. McGuire SE, Levy LB, Settle SH, CHoi S, Nguyen QN, Hoffman KE, Frank SJ, Lee AK, Kuban DA. PSA Response to Neoadjuvant Androgen Suppression Therapy Prior to High Dose Radiotherapy Predicts Survival in Clinically Localized High Risk Prostate Cancer. Int J Rad Oncol Phys 78(3):S124 (#265), 2010.
30. Morikawa L, Levy LB, Lee AK, Choi S, Nguyen QN, Frank SJ, Kuban DA. Relationship Between PSA Failure and Death From Prostate Cancer After Radical External Beam Radiation Therapy. Proceedings of The 40th Jornada Paulista Radiologia, 2010.
31. Nguyen QN, Levy LB, Lee AK, Choi S, Frank SJ, Hoffman KE, Kuban DA. Risk Factors Predicting Failure and Prostate Cancer Mortality in High Risk Prostate Cancer Patients Treated with Definitive External Beam Radiation Therapy. Int J Rad Oncol Phys 78(3):S125 (#266), 2010.
32. Sharp HJ, Levy LB, Kuban DA. The Influence of Race on Presentation and Outcome in Patients Irradiated for Prostate Cancer. Proceedings of the 2010 Genitourinary Cancers Symposium (#155), 2010.
33. Thames HD, Kuban DA, Levy LB. Time Factor for Radiotherapy of Prostate Cancer: Retrospective Analysis of Biochemical Failure in 4839 Men Treated between 1987 and 1995. Int J Rad Oncol Phys 78(3):S127 (#271), 2010.
34. Davis JW, Troncoso P, Ward J, Pettaway C, Pisters L, Kuban D, Brown V, Lothetis C, Kim J. Active Surveillance for Localized Prostate Cancer -- A Prospective Protocol. J Urol 181(4):Suppl 1, 2009.
35. Parker PA, Latini DM, Ward JF, Pettaway C, Pisters LL, Matin S, Frank SJ, Brown V, Kuban DA, Logothetis C, Kim J, Davis JW. Associations Between Uncertainty, Anxiety, and Quality of Life in Men With Prostate Cancer on Active Surveillance. Annals of Behavioral Medicine 37 (#2122), 2009.
36. Vassiliev ON, Kudchadker RJ, Kuban DA, Lee AK. Dosimetric Impact of Gold Fiducial Markers in Patients Undergoing External Beam Radiation Therapy. Proceedings of The American Association of Medical Physics Annual Meeting, 2009.
37. Ludwig MS, Levy LB, Cheung MR, Frank SJ, Lee AK, Nguyen QN, Choi S, Kuban DA. High Risk Prostate Cancer: Outcomes and Adjuvant Hormone Use. Int J Rad Oncol Biol Phys 75(3):S296 (#2257), 2009.
38. Ludwig MS, Kuban DA,. Intermediate Risk Prostate Cancer, Outcomes Related to Radiation Dose and the Use of Hormone Therapy. Proceedings of The 91st Annual Meeting of The American Radium Society, 2009.
39. Fisher CM, Tronsco P, Kuban DA, Munsell MF, Yeh S, Lee AK, Swanson DA, Frank SJ. Knife or Needles? A Matched Cohort Analysis of Low and Intermediate Risk Men Treated Definitively for Adenocarcinoma of the Prostate. Int J Rad Oncol Biol Phys 75(3):S152 (#1063), 2009.
40. Bolukbasi Y, Levy LB, Lee AK, Choi S, Cheung MR, Frank SJ, Nguyen QN, Kuban DA. Long Term Results of Adjuvant and Salvage Radiotherapy after Radical Prostatectomy. Int J Rad Oncol Phys 75(3):S293 (#2251), 2009.
41. Nguyen QN, Levy LD, Lee AK, Choi S, Frank SJ, Cheung MR, Kuban DA. Long-Term Outcome of Patients with High-risk Prostate Cancer Treated Definitively with External Beam Radiation Therapy. Int J Rad Oncol Biol Phys 75(3):S310 (#2286), 2009.
42. Frank SJ, Samuelian J, Swanson DA, Lee AK, Choi S, Cheung M, Nguyen QN, Kudchadker RJ, Bruno TL, Kuban DA. Outcomes in Prostate Cancer Brachytherapy as Monotherapy for Disease at the Prostate Base. Int J Rad Oncol Biol Phys 75(3):S352 (#2381), 2009.
43. Nguyen QN, Levy L, Lee AK, Choi S, Frank SJ, Cheung MR, Kuban DA. Patterns of recurrence in patients diagnosed with high risk prostate cancer treated with external beam radiation therapy. Proceedings of The 91st Annual Meeting of The American Radium Society, 2009.
44. Choi S, Johnson JL, Crevoisier R, Dong L, O'Daniel CO, Frank SJ, Lee AK, Cheung MR, Kuban DA. Quantification of the Volume Change and Iterfractional Motion and Volume of the Prostate for Prostate Cancer Patients Undergoing Concurrent Androgen Deprivation Therapy and Intensity Modulated Radiation Therapy. Int J Rad Oncol Biol Phys 75(3):S597 (#2926), 2009.
45. Morikawa LK, Levy LB, Choi S, Nguyen QN, Cheung MR, Frank SJ, Lee AK, Kuban DA. Relationship Between PSA Failure and Death from Prostate Cancer After Radical External Beam Radiation Therapy. Int J Rad Oncol Phys 75(3):S104 (#221), 2009.
46. Leibovici D, Tu SM, Lopez A, Pagliaro LC, Kuban DA, Logothetis CJ, Pisters LL. The Specific Clinical Characteristics of Ductal Prostate Cancer. J Urol 181(4):Suppl 1, 2009.
47. Kuban, DA. Treatment of Prostate and Urinary Bladder Cancer: The American Perspective. Proceedings of the 2009 JSCO - ASCO Symposium (#JS-3,2009), 2009.
48. Madsen L, Kim J, Craig C, Cheung MR, Kuban DA. A Senior Multidisciplinary Prostate Cancer Clinic - Identifying The Patient Population and Addressing The Treatment Goals. Proceedings of The Oncology Nursing Forum, 2008.
49. Davis J, Troncoso P, Ward J, Babaian J, Pettaway C, Pisters l, Kuban D, Brown V, Logothetis C, Kim J. Active surveillance for clinically localized prostate cancer at high volume tertiary referral center. J Urol 179(4), 2008.
50. Kuban DA, Levy LB, Tucker S, Lee AK, Choi S, Cheung MR, Frank SJ, Pollack A. Long-Term Failure Patterns and Survival in a Randomized Dose Escalation Trial for Prostate Cancer. Who Dies of Disease?. Int J Rad Oncol Biol Phys 72(1):S95 (#206), 2008.
51. O'Daniel JC, Dong L, Kudchadker RJ, Kuban DA, de Crevoisier R, Lee AK, Cheung R, Zhang L, Tucker SL, Mohan R. Daily bone alignment with limited repeat CT correction rivals daily ultrasound alignment for prostate radiotherapy. Int J Radiat Oncol Biol Phys 69:S639, 2007.
52. Madsen L, Craig C, Williams J, Kuban D. Developing a Multidisciplinary Prostate Cancer Clinic for the Newly Diagnosed Prostate cancer Population-defining the role of an oncology APN. Proceedings of the Oncology Nursing Society (#2480), 2007.
53. Cheung MR, Tucker SL, Dong L, Bosch WR, Michalski J, Winter K, Mohan R, Kuban D, Lee AK, Cox JD. Dose-volume analyses pf grade > 2 late rectal toxicity among patients treated on protocol RTOG 94-06. Int J Radiat Oncol Biol Phys 69:S9, 2007.
54. Tucker SL, Dong L, Bosch WR, Michalski J, Winter K, Lee AK, Cheung MR, Kuban DA, Cox JD, Mohan R. Fit of a generalized Lyman normal-tissue complication probability (NTCP) model to grade > 2 late rectal toxicity data from patients treated on protocol RTOG 94-06. Int J Radiat Oncol Biol Phys 69:S8, 2007.
55. Huang E, Pollack A, Levy L, Starkschall G, Dong L, Rosen II, Kuban DA. Late rectal toxicity: Dose-volume effects of conformal radiotherapy for prostate cancer. Health & Safety Science Abstracts, 2007.
56. Sanda MG, Dunn RL, Michalski J, Sandler HM, Hembroff L, Litwin MS, Saigal CS, Mahadevan A, Klein EA, Kibel AS, Pisters LL, Kuban D, Kaplan I, Ciezki JP, Wei JT,. Prostate size, obesity, and neoadjuvant hormone therapy affect HRQOL in a prospective, multi-center study of prostatectomy, external radiotherapy, or brachytherapy for prostate cancer. J Urol(177) (#1772), 2007.
57. Lee AK, Kudchadker RJ, Amos RA, Johnson JL, Choi SL, Kuban DA, Cox JD, Mohan R, Gillin M, Dong L. Proton therapy vs. IMRT for prostate cancer: A dosimetric comparison. Int J Radiat Oncol Biol Phys 69:S342, 2007.
58. Horwitz EM, Hanlon AL, Pisansky TM, Sandler HM, Kuban DA, Catton C, Michalski JM, Stephenson A, Pollack A, Post-Prostatectomy Radiation Therapy Consortium. The Phoenix definition of biochemical failure correlates with clinical failure for men treated with adjuvant and salvage post-prostatectomy radiation: Results of the multi-institutional pooled analysis. Int J Radiat Oncol Biol Phys 69:S173 (#1064), 2007.
59. Lawton CA, Michalski J, El-Naqa I, Kuban D, Lee WR, Rosenthal S, Zietman A, Sandler H, Roach M. Variation in the definition of clinical target volumes for pelvic node conformal radiation therapy of prostate cancer. Int J Radiat Oncol Biol Phys 69:S327, 2007.

Book Chapters

1. Kundra V, Martin S, Kuban D. Prostate Cancer. In: Oncologic Imaging: A Multidisciplinary Approach. Ed(s) Silverman P. Elsevier - Saunders: Philadelphia, PA, 377 - 402, 2012.
2. Michalski J, Potters L, Lawton CA, Pisansky TM, Kuban DA. Prostate Cancer. In: Clinical Radiation Oncology. Third Edition. Ed(s) D Meloni, MB Murphy, J Patterson, MG Stueck, L Forgione. Churchill Livingston, an imprint of Elsevier, Inc. Philadelphia, PA, 1037 - 1097, 2011.
3. Logothetis CJ, Troncoso P, Kim J, Davis JW, Kuban DA, Mathew P, Aparicio A. Neoplasms of the Prostate. In: Cancer Medicine 8th Edition. PMPH-USA: Shelton, CT, 1228 - 1254, 2010.
4. Kuban DA, Trad ML. Male Reproductive and Genitourinary Tumors. In: Principles and Practice of Radiation Therapy. Mosby, Inc. St. Louis, MO, 823 - 865, 2009.
5. Kuban DA, Cheung R, Meistrich ML, Hussey DH. The Testicle. In: Radiation Oncology: Rationale, Technique, Results. Mosby, Inc. St. Louis, MO, 653 - 675, 2009.
6. Kuban DA, Potters L, Lawton CA, Pisansky TM. Prostate Cancer. In: Clinical Radiation Oncology. Churchill Livingston an imprint of Elsevier, Inc. Philadelphia, PA, 1165 - 1236, 2007.

Letters to the Editor

1. Kuban DA. In reply to Drs. Schulz and Kagan. Int J Radiat Oncol Biol Phys. 71(4):1288, 2008.

Manuals, Teaching Aids, Other Teaching Publications

1. Volk R, Pettaway C, Kuban D. Knowing Your Options: A Decision Aid for Men with Clinically Localized Prostate Cancer. A Patient Decision Aid Released by AHRO, http://www.effectivenesshealthcare.ahrq.gov/ehc/decisionaids/prostate-cancer/?EC=MDA, 9/2011.
2. Chan EC, McFall SL, Byrd TL, Mullen PD, Volk RJ, Ureda J, Calderon-Mora J, Morales P, Valdes A, Kay Bartholomew L. A community-based intervention to promote informed decision making for prostate cancer screening among Hispanic American men changed knowledge and role preferences: a cluster RCT. 2, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=21237611. e-Pub 1/14/2011. PMID: 21237611.
3. Kuban DA,. Multidisciplinary Prostate Cancer Clinic. A Guide to Treatment Options. Ed(s) Kuban DA., 2008.
4. Kuban DA. Genitourinary Radiation Guide. U. T. M. D. Anderson Cancer Center, Dept of Radiation Oncology, 2003.
 

Other

1. The University of Texas M.D. Anderson Website. "Genitourinary Radiation Guide", 2003.
2. The University of Texas M.D. Anderson Website. Production and Editing Video - "How to Treat Cancer", 2004-2005.
3. Consultant for Genitourinary Center Website. Prostate Cancer, Kidney Cancer, Bladder Cancer, and Testicular Cancer, 2004-2005.
4. Participant in video. Prostate Cancer, supported by Texas Health Council, 2004-2005.
5. Author. Development and update of M. D. Anderson Clinical Guidelines for Prostate, Bladder and Renal Cancer, 2001 - present.
6. The University of Texas M.D. Anderson Website. Multidisciplinary Prostate Cancer Clinic, 2008.
7. The University of Texas M.D. Anderson Website. Advances in the Treatment of Prostate Cancer. Patient Power, Weekly Web-based talk Radio Show hosted by Andrew Schorr, 2007.
8. The University of Texas M.D. Anderson Website. Video - Focus on Prostate Cancer, 2010.
9. The University of Texas M.D. Anderson Website. Radiation Treatment for Prostate Cancer. Patient Power, Weekly web-based talk radio show hosted by Andrew Schorr, 2010.

Grant & Contract Support

Title: Impact of Multidisciplinary Prostate Cancer Clinic Visit
Funding Source: Texas US Too
Role: Co-Investigator
Principal Investigator: Hoffman
Duration: 7/1/2013 - 6/30/2014
 
Title: Comparative Effectiveness of Treatments for Localized Prostate Cancer
Funding Source: Recovery Act 2009 AHRQ Choice Grant
Role: Co-Investigator
Principal Investigator: Penson D
Duration: 8/1/2011 - 7/1/2013
 
Title: Acceptability of Active Surveillance as a Treatment Choice for Prostate Cancer among U.S. Men
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Volk, R
Duration: 9/1/2009 - 9/1/2012
 
Title: Efficacy of Cancer Support Group Programs: A Social Comparison Theory Analysis.
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Carmack-Taylor, C
Duration: 7/1/2008 - 6/30/2010
 
Title: A Comprehensive, Multimodality Quality of Life Study for Prostate Cancer
Funding Source: UTMDACC Prostate Cancer Research Program
Role: Principal Investigator
Duration: 1/1/2008 - 12/1/2012
 
Title: Evaluating the role of genetic makers in prostate cancer progression
Funding Source: Department of Defense (DOD)
Role: Co-Investigator
Principal Investigator: Strom S
Duration: 9/4/2007 - 10/3/2010
 
Title: Real-time in vivo Dosimetry in Radiation Therapy using Scintillation Detectors
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Beddar, S
Duration: 7/1/2007 - 5/31/2010
 
Title: Optimizing the Delivery of Lifestyle Interventions in Cancer Survivors
Funding Source: U.T.M.D. Anderson Multidisciplinary Research Program
Role: Co-Investigator
Principal Investigator: Demark-Wahnefried, W Basen-Engquist, K
 
Title: CCSG Core Grant
Funding Source: U. T. M. D. Anderson Cancer Center
Role: Associate Program Member

Last updated: 8/9/2013